Total Payments
$534,206
2024 Payments
$42,180
Companies
44
Transactions
368
Medicare Patients
12,470
Medicare Billing
$2.3M
Payment Breakdown by Category
Research$292,477 (54.7%)
Other$183,875 (34.4%)
Consulting$34,608 (6.5%)
Travel$14,187 (2.7%)
Food & Beverage$8,840 (1.7%)
Education$219.59 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $292,477 | 21 | 54.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $178,188 | 76 | 33.4% |
| Consulting Fee | $34,608 | 20 | 6.5% |
| Travel and Lodging | $14,187 | 36 | 2.7% |
| Food and Beverage | $8,840 | 205 | 1.7% |
| Honoraria | $5,688 | 3 | 1.1% |
| Education | $219.59 | 7 | 0.0% |
Payments by Type
Research
$292,477
21 transactions
General
$241,729
347 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $274,995 | 18 | $0 (2024) |
| Janssen Biotech, Inc. | $121,802 | 121 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $51,363 | 57 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $32,596 | 22 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $17,479 | 11 | $0 (2022) |
| ABBVIE INC. | $9,281 | 23 | $0 (2024) |
| Amgen Inc. | $6,399 | 10 | $0 (2018) |
| Acerta Pharma LLC | $3,823 | 2 | $0 (2019) |
| Epizyme, Inc., | $3,750 | 2 | $0 (2021) |
| Seagen Inc. | $2,438 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $42,180 | 66 | Janssen Biotech, Inc. ($39,300) |
| 2023 | $27,239 | 46 | Janssen Biotech, Inc. ($15,885) |
| 2022 | $29,355 | 34 | Janssen Biotech, Inc. ($20,815) |
| 2021 | $20,161 | 32 | AstraZeneca Pharmaceuticals LP ($8,339) |
| 2020 | $13,175 | 20 | Janssen Biotech, Inc. ($4,392) |
| 2019 | $73,739 | 57 | Janssen Biotech, Inc. ($26,503) |
| 2018 | $179,855 | 91 | Celgene Corporation ($115,860) |
| 2017 | $148,501 | 22 | Celgene Corporation ($145,984) |
All Payment Transactions
368 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $825.00 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $16.31 | General |
| Category: Hematology | ||||||
| 12/10/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $26.71 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | Cash or cash equivalent | $217.75 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,125.00 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), BALVERSA | Food and Beverage | In-kind items and services | $12.46 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Education | In-kind items and services | $17.02 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $19.09 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,575.00 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,125.00 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $1,009.16 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $96.94 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $19.73 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $14.97 | General |
| Category: Oncology / Rare Diseases | ||||||
| 10/16/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $17.43 | General |
| Category: Oncology | ||||||
| 10/15/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $24.21 | General |
| Category: Oncology | ||||||
| 10/15/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $2.69 | General |
| Category: Oncology | ||||||
| 10/10/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $5.50 | General |
| Category: Oncology | ||||||
| 10/09/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $21.85 | General |
| Category: Oncology | ||||||
| 10/01/2024 | CSL Behring | HEMGENIX (Biological) | Food and Beverage | In-kind items and services | $22.88 | General |
| Category: Hematology | ||||||
| 09/19/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $17.98 | General |
| Category: ONCOLOGY | ||||||
| 09/06/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $37.13 | General |
| Category: ONCOLOGY | ||||||
| 09/05/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $114.90 | General |
| Category: Oncology | ||||||
| 09/05/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $62.09 | General |
| Category: Oncology | ||||||
| 09/05/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $34.84 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CC-5013-NHL-008 | Celgene Corporation | $144,521 | 2 |
| CC-5013-NHL-008 - A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicu | Celgene Corporation | $111,242 | 2 |
| A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) (CC-5013-NHL-008) | Celgene Corporation | $13,119 | 2 |
| Pevonedistat-3001 PANTHER North and Latin American Investigator Meeting - All Day Beverages 4-20 | Takeda Pharmaceuticals U.S.A., Inc. | $12,544 | 4 |
| The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma INSIGHT | Takeda Pharmaceuticals U.S.A., Inc. | $4,880 | 5 |
| A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia | Acerta Pharma LLC | $3,823 | 2 |
| AG-221-AML-004 | Celgene Corporation | $1,463 | 1 |
| A Phase 1 2a Study of BMS 986253 in Combination with Nivolumab in Advanced Cancers | E.R. Squibb & Sons, L.L.C. | $95.00 | 1 |
| An Investigational Immunotherapy Study of BMS 986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread | E.R. Squibb & Sons, L.L.C. | $90.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 51 | 2,747 | 26,799 | $1.4M | $275,516 |
| 2022 | 63 | 3,526 | 50,124 | $2.9M | $569,947 |
| 2021 | 62 | 3,466 | 57,841 | $3.3M | $657,533 |
| 2020 | 59 | 2,731 | 40,708 | $3.1M | $759,509 |
Total Patients
12,470
Total Services
175,472
Medicare Billing
$2.3M
Procedure Codes
235
All Medicare Procedures & Services
235 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 15 | 2,580 | $172,080 | $47,933 | 27.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 172 | 346 | $127,328 | $32,332 | 25.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 78 | 170 | $84,320 | $22,652 | 26.9% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 12 | 8,725 | $174,500 | $20,597 | 11.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 214 | 327 | $81,750 | $20,195 | 24.7% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 11 | 15 | $72,030 | $18,442 | 25.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 72 | 166 | $117,362 | $17,810 | 15.2% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 17 | 35 | $60,270 | $12,027 | 20.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 329 | 997 | $19,940 | $8,375 | 42.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 267 | 730 | $46,720 | $7,531 | 16.1% |
| 83521 | Measurement of immunoglobulin light chains | Office | 2023 | 77 | 428 | $25,680 | $7,244 | 28.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 305 | 810 | $29,160 | $6,134 | 21.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 48 | 105 | $32,865 | $5,379 | 16.4% |
| 85055 | Reticulated (young) platelet measurement | Office | 2023 | 49 | 134 | $19,162 | $4,694 | 24.5% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 20 | 76 | $16,036 | $4,565 | 28.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 57 | 191 | $29,987 | $4,528 | 15.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $11,344 | $2,612 | 23.0% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 27 | 49 | $16,856 | $2,600 | 15.4% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 19 | 23 | $15,111 | $2,079 | 13.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 30 | 89 | $14,329 | $2,052 | 14.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $9,040 | $1,889 | 20.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 13 | $9,022 | $1,772 | 19.6% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2023 | 48 | 81 | $10,368 | $1,652 | 15.9% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 13 | 30 | $8,670 | $1,366 | 15.8% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 60 | 103 | $6,180 | $1,355 | 21.9% |
About Dr. Jason Melear, M.D
Dr. Jason Melear, M.D is a Medical Oncology healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1902849805.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jason Melear, M.D has received a total of $534,206 in payments from pharmaceutical and medical device companies, with $42,180 received in 2024. These payments were reported across 368 transactions from 44 companies. The most common payment nature is "" ($292,477).
As a Medicare-enrolled provider, Melear has provided services to 12,470 Medicare beneficiaries, totaling 175,472 services with total Medicare billing of $2.3M. Data is available for 4 years (2020–2023), covering 235 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Austin, TX
- Active Since 06/14/2006
- Last Updated 10/01/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1902849805
Products in Payments
- Revlimid (Drug) $268,881
- DARZALEX (Biological) $150,036
- CALQUENCE (Drug) $55,116
- Kyprolis (Biological) $6,350
- TECVAYLI (Biological) $4,130
- TAZVERIK (Drug) $3,750
- ADCETRIS (Biological) $2,421
- Venclexta (Drug) $2,070
- XPOVIO (Drug) $1,961
- SARCLISA (Biological) $1,913
- SCEMBLIX (Drug) $1,860
- Idhifa (Drug) $1,463
- VENCLEXTA (Drug) $1,400
- Non-Covered Product (Drug) $855.93
- ERLEADA (Drug) $162.86
- BRUKINSA (Drug) $135.89
- Epkinly (Drug) $114.90
- KEYTRUDA (Biological) $111.79
- AYVAKIT (Drug) $100.32
- iDrive (Device) $96.42
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Austin
Sue Eckhardt, Md, MD
Medical Oncology — Payments: $419,765
Medical Oncology $419,765
Miguel Albino, Md, MD
Medical Oncology — Payments: $308,516
Medical Oncology $308,516
Michael Lattanzi
Medical Oncology — Payments: $155,982
Medical Oncology $155,982
Dr. Aravind Ramakrishnan, M.d, M.D
Medical Oncology — Payments: $110,197
Medical Oncology $110,197
Dr. Laurence Tokaz, M.d, M.D
Medical Oncology — Payments: $46,331
Medical Oncology $46,331
Dr. John Sandbach, Md, MD
Medical Oncology — Payments: $7,649
Medical Oncology $7,649